Galectin Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
GALT Nasdaq 2834 http://www.galectintherapeutics.com 15.15 Stock Down -0.78

Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galectin Therapeutics Inc

Fatty Liver Disease Should Keep Stocks Moving In 2014 - Mar 7th, 2014 3:02 pm
Nasdaq stocks posting largest percentage increases - Mar 7th, 2014 11:23 am
Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar Therapeutics - Feb 27th, 2014 7:27 am
Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease - Feb 26th, 2014 7:46 am
Galectin Therapeutics secures GR-MD-02 U.S. patent - Feb 26th, 2014 6:07 am
Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease - Feb 26th, 2014 6:00 am
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 26th, 2014 5:46 am
Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop - Feb 24th, 2014 8:00 am
Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference - Feb 13th, 2014 6:00 am
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 13th, 2014 5:47 am
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 10th, 2014 2:02 pm
Galectin Therapeutics price target raised $32 from $16 at Aegis - Feb 10th, 2014 8:23 am
Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference - Feb 5th, 2014 8:09 am
Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference - Feb 5th, 2014 6:15 am
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - Feb 5th, 2014 6:01 am
Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma - Feb 3rd, 2014 9:46 am
Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma - Feb 3rd, 2014 9:30 am
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits - Feb 3rd, 2014 8:57 am
Intercept’s Fibrosis Success Gives Galectin High Hope - Jan 28th, 2014 10:02 am
Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration - Jan 27th, 2014 6:15 am